Plasma level of cardiotrophin-1 as a prognostic predictor in patients with chronic heart failure

详细信息	查看全文 | 推荐本文 |

• 作者：Takayoshi Tsutamoto ; Shigeru Asai ; Toshinari Tanaka ; Hiroshi Sakai ; Keizo Nishiyama ; Masanori Fujii ; Takashi Yamamoto ; Masato Ohnishi ; Atsuyuki Wada ; Yoshihiko Saito ; Minoru Horie
• 关键词：Cardiotrophin-1 ; Brain natriuretic peptide ; Heart failure ; Prognosis ; Interleukin 6
• 刊名：European Journal of Heart Failure
• 出版年：2007
• 期刊代码：90_13889842
• 类别：med
• 出版时间：October 2007
• 卷：9
• 期：10
• 页码：1032-1037
• 文件大小：258 K

摘要

Cardiotrophin-1 (CT-1) is a member of the interleukin (IL-6) family of cytokines and is increased in patients with chronic heart failure (CHF).

Aims

To evaluate the prognostic role of CT-1 in patients with CHF.

Methods and results

We measured the plasma levels of CT-1, brain natriuretic peptide (BNP), and IL-6 in 125 patients with CHF. Patients were monitored for a mean follow-up period of 2.9 years. Plasma levels of CT-1 increased with severity of CHF. There was a significant negative correlation between plasma CT-1 and left ventricular ejection fraction. There was a significant correlation between plasma CT-1 and log IL-6. During the follow-up period, 37 patients died. High plasma levels of CT-1, BNP, and IL-6 were independent predictors of mortality on stepwise multivariate analysis. The hazard ratio for mortality in patients with plasma BNP > 170 pg/mL and CT-1 > 658 fmol/mL was 2.48 (95%confidence interval, 1.217–5.060) compared to those with plasma BNP > 170 pg/mL and CT-1 < 658 fmol/mL (p = 0.0124).

Conclusion

These findings indicate that plasma CT-1 measurement provides additional prognostic information and that combined levels of CT-1 and BNP are more accurate at predicting mortality in patients with CHF than either marker alone.